Ehrsam Jonas Peter, Meier Adamenko Olga, Pannu Manjinder, Markus Schöb Othmar, Inci Ilhan
School of Medicine, University of Zurich, Zurich, Switzerland.
Department of Thoracic Surgery, Klinik Hirslanden Zurich, Zurich, Switzerland.
Turk Gogus Kalp Damar Cerrahisi Derg. 2024 Feb 5;32(Suppl1):S119-S133. doi: 10.5606/tgkdc.dergisi.2024.25806. eCollection 2024 Jan.
Lung transplantation is a well-established treatment for children facing advanced lung disease and pulmonary vascular disorders. However, organ shortage remains highest in children. For fitting the small chest of children, transplantation of downsized adult lungs, lobes, or even segments were successfully established. The worldwide median survival after pediatric lung transplantation is currently 5.7 years, while under consideration of age, underlying disease, and peri- and posttransplant center experience, median survival of more than 10 years is reported. Timing of referral for transplantation, ischemia-reperfusion injury, primary graft dysfunction, and acute and chronic rejection after transplantation remain the main challenges.
肺移植是治疗患有晚期肺部疾病和肺血管疾病儿童的一种成熟疗法。然而,儿童器官短缺问题最为严重。为了适配儿童的小胸腔,已成功开展了缩小尺寸的成人肺、肺叶甚至肺段的移植。目前,全球儿童肺移植后的中位生存期为5.7年,但若考虑年龄、基础疾病以及移植前后中心的经验,有报告称中位生存期超过10年。移植转诊时机、缺血再灌注损伤、原发性移植物功能障碍以及移植后的急慢性排斥反应仍是主要挑战。